JP5783908B2 - 攻撃性を治療する方法 - Google Patents
攻撃性を治療する方法 Download PDFInfo
- Publication number
- JP5783908B2 JP5783908B2 JP2011542480A JP2011542480A JP5783908B2 JP 5783908 B2 JP5783908 B2 JP 5783908B2 JP 2011542480 A JP2011542480 A JP 2011542480A JP 2011542480 A JP2011542480 A JP 2011542480A JP 5783908 B2 JP5783908 B2 JP 5783908B2
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- dose
- day
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
本願は、2008年12月19日付けで出願された米国仮出願第61/193,735号からの優先権を主張するものである。
モリンドンの有効性、安全性及び許容性を、ADHD及び持続性重度行為問題の小児における無作為化多施設並行群間用量範囲研究において評価した。被験体をベースライン時の体重に基づいて無作為に1〜4の治療群に割り付けた。体重30kg未満の被験体に対する投薬は1.67mg/日で開始し、体重30kg以上の被験体については3.34mg/日で開始した。目標用量(治療群1、治療群2、治療群3又は治療群4)に達するまで滴定スケジュールに従った。被験体を6週間目標用量に維持した(表9)。
Claims (6)
- ADHDと診断された小児における衝動的攻撃性を治療するための医薬品であって、前記医薬品がモリンドンを含む、医薬品。
- 統合失調症の治療薬としてのモリンドンの使用に指示される用量の50%以下の用量で投与される、請求項1に記載の医薬品。
- 5mg/日〜20mg/日の用量範囲で投与される、請求項1又は2に記載の医薬品。
- モリンドン投与に伴う副作用が減少された、請求項2に記載の医薬品。
- 眠気、鬱状態、活動過多、陶酔感、錐体外路反応、静坐不能、運動不能、ジストニー症候群、遅発性ジスキネジア、頻脈、嘔気、口渇、尿閉及び便秘から選択される少なくとも1つの副作用の発生数が減少された、請求項4に記載の医薬品。
- 前記医薬品が望ましくない行動の減少及び許容可能な副作用をもたらす、請求項2に記載の医薬品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19373508P | 2008-12-19 | 2008-12-19 | |
US61/193,735 | 2008-12-19 | ||
PCT/US2009/068707 WO2010080603A2 (en) | 2008-12-19 | 2009-12-18 | Method of treatment of aggression |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015094975A Division JP6133354B2 (ja) | 2008-12-19 | 2015-05-07 | 攻撃性を治療する方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012512897A JP2012512897A (ja) | 2012-06-07 |
JP2012512897A5 JP2012512897A5 (ja) | 2013-03-07 |
JP5783908B2 true JP5783908B2 (ja) | 2015-09-24 |
Family
ID=42312104
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011542480A Active JP5783908B2 (ja) | 2008-12-19 | 2009-12-18 | 攻撃性を治療する方法 |
JP2015094975A Expired - Fee Related JP6133354B2 (ja) | 2008-12-19 | 2015-05-07 | 攻撃性を治療する方法 |
JP2017081899A Expired - Fee Related JP6316480B2 (ja) | 2008-12-19 | 2017-04-18 | 攻撃性を治療する方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015094975A Expired - Fee Related JP6133354B2 (ja) | 2008-12-19 | 2015-05-07 | 攻撃性を治療する方法 |
JP2017081899A Expired - Fee Related JP6316480B2 (ja) | 2008-12-19 | 2017-04-18 | 攻撃性を治療する方法 |
Country Status (7)
Country | Link |
---|---|
US (5) | US20100173907A1 (ja) |
EP (1) | EP2367544A4 (ja) |
JP (3) | JP5783908B2 (ja) |
AU (3) | AU2009335709A1 (ja) |
CA (2) | CA2746509C (ja) |
MX (4) | MX2019001413A (ja) |
WO (1) | WO2010080603A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015164942A (ja) * | 2008-12-19 | 2015-09-17 | スパーナス ファーマシューティカルズ インコーポレイテッド | 攻撃性を治療する方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10310415A1 (de) * | 2003-03-11 | 2004-09-30 | Bayer Ag | Verfahren zur An- und Abmeldung von Produkten und deren gefärbten Einstellungen |
EP3269363B1 (en) | 2010-03-31 | 2019-08-28 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of cns compounds |
MX2015005937A (es) * | 2012-11-13 | 2015-09-08 | Supernus Pharmaceuticals Inc | Metodo de tratamiento de la agresion. |
WO2017189892A1 (en) * | 2016-04-29 | 2017-11-02 | Supernus Pharmaceuticals, Inc. | Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148896A (en) | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US6489319B2 (en) | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
JP3893058B2 (ja) | 1999-09-30 | 2007-03-14 | ペンウェスト ファーマシューティカルズ カンパニー | 高度に可溶性の薬物のための徐放性マトリックス系 |
FR2814463B1 (fr) | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
US6613763B2 (en) | 2001-04-20 | 2003-09-02 | Mgi Applied Genomics | Use of molindone to treat oppositional defiant disorder and conduct disorder |
JP4994570B2 (ja) | 2001-07-04 | 2012-08-08 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | 胃保持制御ドラッグデリバリーシステム |
DE10149108A1 (de) | 2001-10-05 | 2003-04-30 | Degussa Bioactives Deutschland | Verwendung von Phosphatidylserin zur Behandlung des Aufmerksamkeits-Defizit-Syndroms (ADHS) |
WO2004050068A1 (en) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
CA2506807A1 (en) | 2002-12-13 | 2004-07-01 | Cilag Ag | Controlled release preparations comprising tramadol and topiramate |
WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
US7761144B2 (en) | 2004-03-18 | 2010-07-20 | University Of Virginia Patent Foundation | Method, apparatus, and computer program product for stochastic psycho-physiological assessment of attentional impairments |
CA2566154A1 (en) | 2004-05-27 | 2005-12-08 | Warner-Lambert Company Llc | Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders |
PT1761514E (pt) | 2004-06-14 | 2008-10-28 | Janssen Pharmaceutica Nv | Novos derivados de tetra-hidrofurano tetracíclicos |
US20090208579A1 (en) | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
KR101468053B1 (ko) | 2006-08-31 | 2014-12-02 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템 |
JP2008189616A (ja) * | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | 注意欠陥多動性障害の治療薬 |
GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
US8637080B2 (en) * | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
CA2746509C (en) | 2008-12-19 | 2018-11-20 | Supernus Pharmaceuticals, Inc. | Use of molindone for the treatment of impulsive agression |
EP3269363B1 (en) | 2010-03-31 | 2019-08-28 | Supernus Pharmaceuticals, Inc. | Stabilized formulations of cns compounds |
SE536078C2 (sv) | 2010-10-09 | 2013-04-30 | Core Link Ab | Anordning för bearbetning av hylsor |
MX2015005937A (es) | 2012-11-13 | 2015-09-08 | Supernus Pharmaceuticals Inc | Metodo de tratamiento de la agresion. |
-
2009
- 2009-12-18 CA CA2746509A patent/CA2746509C/en active Active
- 2009-12-18 EP EP09837980.3A patent/EP2367544A4/en not_active Withdrawn
- 2009-12-18 WO PCT/US2009/068707 patent/WO2010080603A2/en active Application Filing
- 2009-12-18 MX MX2019001413A patent/MX2019001413A/es unknown
- 2009-12-18 CA CA3014688A patent/CA3014688A1/en not_active Abandoned
- 2009-12-18 US US12/654,455 patent/US20100173907A1/en not_active Abandoned
- 2009-12-18 JP JP2011542480A patent/JP5783908B2/ja active Active
- 2009-12-18 AU AU2009335709A patent/AU2009335709A1/en not_active Abandoned
- 2009-12-18 MX MX2014010480A patent/MX362853B/es unknown
- 2009-12-18 MX MX2011006463A patent/MX2011006463A/es active IP Right Grant
-
2011
- 2011-06-16 MX MX2021013281A patent/MX2021013281A/es unknown
-
2013
- 2013-07-26 US US13/951,642 patent/US9801887B2/en active Active
-
2015
- 2015-05-07 JP JP2015094975A patent/JP6133354B2/ja not_active Expired - Fee Related
- 2015-08-31 AU AU2015221441A patent/AU2015221441C1/en not_active Ceased
-
2017
- 2017-04-18 JP JP2017081899A patent/JP6316480B2/ja not_active Expired - Fee Related
- 2017-06-22 AU AU2017204229A patent/AU2017204229B2/en not_active Ceased
- 2017-10-12 US US15/782,334 patent/US10058556B2/en active Active
-
2018
- 2018-07-26 US US16/046,858 patent/US10201547B2/en active Active
-
2019
- 2019-01-04 US US16/240,389 patent/US11638708B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015164942A (ja) * | 2008-12-19 | 2015-09-17 | スパーナス ファーマシューティカルズ インコーポレイテッド | 攻撃性を治療する方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6316480B2 (ja) | 2018-04-25 |
AU2017204229A1 (en) | 2017-07-13 |
AU2009335709A1 (en) | 2011-07-14 |
EP2367544A2 (en) | 2011-09-28 |
AU2015221441B2 (en) | 2017-06-15 |
US20100173907A1 (en) | 2010-07-08 |
US11638708B2 (en) | 2023-05-02 |
AU2015221441C1 (en) | 2017-09-21 |
JP2017149757A (ja) | 2017-08-31 |
US20140187552A1 (en) | 2014-07-03 |
US10058556B2 (en) | 2018-08-28 |
CA2746509A1 (en) | 2010-07-15 |
MX2019001413A (es) | 2019-08-12 |
US9801887B2 (en) | 2017-10-31 |
JP2015164942A (ja) | 2015-09-17 |
AU2017204229B2 (en) | 2018-05-31 |
WO2010080603A9 (en) | 2010-11-18 |
CA2746509C (en) | 2018-11-20 |
US20180325912A1 (en) | 2018-11-15 |
MX2021013281A (es) | 2022-06-02 |
JP2012512897A (ja) | 2012-06-07 |
US20180055853A1 (en) | 2018-03-01 |
US20200022986A1 (en) | 2020-01-23 |
EP2367544A4 (en) | 2016-06-08 |
AU2015221441A1 (en) | 2015-09-17 |
WO2010080603A2 (en) | 2010-07-15 |
US10201547B2 (en) | 2019-02-12 |
MX362853B (es) | 2019-02-20 |
MX2011006463A (es) | 2011-07-20 |
CA3014688A1 (en) | 2010-07-15 |
JP6133354B2 (ja) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6316480B2 (ja) | 攻撃性を治療する方法 | |
Vocci et al. | Medications development: successes and challenges | |
Chatterjee et al. | Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders | |
FEIGHNER et al. | Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder | |
Bahi | The oxytocin receptor impairs ethanol reward in mice | |
Visanji et al. | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease | |
Galletly | Recent advances in treating cognitive impairment in schizophrenia | |
Lasser et al. | Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial | |
Findling et al. | Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial | |
Chen et al. | Minocycline affects cocaine sensitization in mice | |
AU2018202636A1 (en) | Method of treatment of aggression | |
George et al. | Successful Treatment of Tourette Syndrome With a Combination of Guanfacine and Aripiprazole: A Case Series | |
Kudo et al. | Galantamine for Alzheimer’s disease and Alzheimer’s disease with cerebrovascular disease | |
Wiesbeck | Dopaminergic compounds: clinical data | |
Kufahl et al. | Potential use of antidepressants as therapies for drug use disorders | |
Lasich | LOFEPRAMINE IN THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER | |
Rosenhagen et al. | New Frontiers in Ketamine Research: From Mechanisms of Action to Novel Psychiatric Treatment Approaches |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141030 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150507 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150714 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150721 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5783908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |